Health-related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine

Eight-hundred forty-nine patients with symptomatic nonerosive GERD from two clinical trials of lansoprazole 15 mg daily (LAN 15) and lansoprazole 30 m g daily (LAN 30) vs ranitidine 150 mg twice a day (RAN 150) completed a hea lth-related quality-of-life (HRQoL) questionnaire at baseline and four and eight weeks after treatment. The questionnaire included the Short-Form 12, GERD symptoms, eating symptoms, social restrictions, problems with sleep, w ork disability, treatment satisfaction, and associated importance weights i tems. Both LAN groups reported greater, although not significant, improveme nt from baseline to week 8 versus RAN 150 in the majority of HRQoL scales. Treatment satisfaction was significantly higher at week 8 in both LAN group s. Quality-days incrementally gained analysis showed that both LAN groups g ained significantly more quality days than RAN 150. Patients taking lansopr azole 15 or 30 mg daily reported better outcomes than those receiving ranit idine 150 twice a day over the eight-week study.